Advertisement
Screener

SAB BIOTHERAPEUTICS, INC. (SABS) Interest Income, Other

2.8 / 5 stars · 68/120 Roast Me

SAB BIOTHERAPEUTICS, INC. Interest Income, Other

SAB BIOTHERAPEUTICS, INC. (SABS) reported Interest Income, Other of $1.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement › Other Income

us-gaap:InterestIncomeOther · last filed 2026-08-06

  • SAB BIOTHERAPEUTICS, INC. interest income, other for the quarter ending 2026-06-30 was $1.71M, a 12107.14% increase year-over-year.
  • SAB BIOTHERAPEUTICS, INC. interest income, other for the quarter ending 2026-03-31 was $1.05M, a 1575.57% increase year-over-year.
  • SAB BIOTHERAPEUTICS, INC. interest income, other for the quarter ending 2025-12-31 was $700.74K, a 413.84% increase year-over-year.
  • SAB BIOTHERAPEUTICS, INC. interest income, other for the quarter ending 2025-09-30 was $655.23K, a 136.40% increase year-over-year.
  • SAB BIOTHERAPEUTICS, INC. interest income, other for fiscal 2025 was $1.43M, a 11.36% increase from fiscal 2024.
  • SAB BIOTHERAPEUTICS, INC. interest income, other for fiscal 2024 was $1.29M, a 119.84% increase from fiscal 2023.
  • SAB BIOTHERAPEUTICS, INC. interest income, other for fiscal 2023 was $584.97K, a 723.06% increase from fiscal 2022.
  • SAB BIOTHERAPEUTICS, INC. interest income, other for fiscal 2022 was $71.07K, a 207.47% increase from fiscal 2021.
Period endInterest Income, Other 3 monthInterest Income, Other 3 month as first filedInterest Income, Other 6 monthInterest Income, Other 6 month as first filedInterest Income, Other 9 monthInterest Income, Other 9 month as first filedInterest Income, Other 12 month
2026-06-30$1.71M
10-Q · filed 2026-08-06
$2.76M
10-Q · filed 2026-08-06
$3.46M
derived: sum of 3 quarters · filed 2026-08-06
$4.11M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$1.05M
10-Q · filed 2026-05-12
$1.75M
derived: sum of 2 quarters · filed 2026-05-12
$2.40M
derived: sum of 3 quarters · filed 2026-05-12
$2.42M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$700.74K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
$1.36M
derived: sum of 2 quarters · filed 2026-03-09
$1.37M
derived: sum of 3 quarters · filed 2026-08-06
$1.43M
10-K · filed 2026-03-09
2025-09-30$655.23K
10-Q · filed 2025-11-14
$669.23K
derived: sum of 2 quarters · filed 2026-08-06
$731.29K
10-Q · filed 2025-11-14
$868.11K
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$14.00K
10-Q · filed 2026-08-06
$13.56K
10-Q · filed 2025-08-07
$76.00K
10-Q · filed 2026-08-06
$76.06K
10-Q · filed 2025-08-07
$212.87K
derived: sum of 3 quarters · filed 2026-08-06
$490.05K
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$62.50K
10-Q · filed 2026-05-12
$198.87K
derived: sum of 2 quarters · filed 2026-05-12
$476.05K
derived: sum of 3 quarters · filed 2026-05-12
$850.60K
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31$136.37K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
$413.55K
derived: sum of 2 quarters · filed 2026-03-09
$788.11K
derived: sum of 3 quarters · filed 2026-03-09
$1.29M
10-K · filed 2026-03-09
2024-09-30$277.17K
10-Q · filed 2025-11-14
$651.73K
derived: sum of 2 quarters · filed 2025-11-14
$1.15M
10-Q · filed 2025-11-14
$1.63M
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30$374.56K
10-Q · filed 2025-08-07
$872.45K
10-Q · filed 2025-08-07
$1.36M
derived: sum of 3 quarters · filed 2025-08-07
$1.37M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31$497.89K
10-Q · filed 2025-05-09
$981.94K
derived: sum of 2 quarters · filed 2025-05-09
$996.30K
derived: sum of 3 quarters · filed 2025-05-09
$1.02M
derived: sum of 4 quarters · filed 2025-05-09
2023-12-31$484.05K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$498.41K
derived: sum of 2 quarters · filed 2025-03-31
$526.98K
derived: sum of 3 quarters · filed 2025-03-31
$584.97K
10-K · filed 2025-03-31
2023-09-30$14.36K
10-Q · filed 2024-11-06
$42.93K
derived: sum of 2 quarters · filed 2024-11-06
$100.92K
10-Q · filed 2024-11-06
$130.85K
derived: sum of 4 quarters · filed 2024-11-06
2023-06-30$28.57K
10-Q · filed 2024-08-08
$86.56K
10-Q · filed 2024-08-08
$116.48K
derived: sum of 3 quarters · filed 2024-08-08
$133.87K
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31$57.99K
10-Q · filed 2024-05-20
$87.92K
derived: sum of 2 quarters · filed 2024-05-20
$105.30K
derived: sum of 3 quarters · filed 2024-05-20
$121.13K
derived: sum of 4 quarters · filed 2024-05-20
2022-12-31$29.93K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
$47.31K
derived: sum of 2 quarters · filed 2024-03-29
$63.14K
derived: sum of 3 quarters · filed 2024-03-29
$71.07K
10-K · filed 2024-03-29
2022-09-30$17.39K
10-Q · filed 2023-11-13
$33.21K
derived: sum of 2 quarters · filed 2023-11-13
$41.14K
10-Q · filed 2023-11-13
$49.69K
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$15.82K
10-Q · filed 2023-08-21
$23.76K
10-Q · filed 2023-08-21
$32.30K
derived: sum of 3 quarters · filed 2023-08-21
$36.07K
derived: sum of 4 quarters · filed 2023-08-21
2022-03-31$7.93K
10-Q · filed 2023-05-15
$16.48K
derived: sum of 2 quarters · filed 2023-05-15
$20.25K
derived: sum of 3 quarters · filed 2023-05-15
$25.54K
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31$8.54K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28
$12.31K
derived: sum of 2 quarters · filed 2023-04-28
$17.61K
derived: sum of 3 quarters · filed 2023-04-28
$23.11K
10-K/A · filed 2023-04-28
2021-09-30$3.77K
10-Q · filed 2022-11-14
$2.93K
10-Q · filed 2021-11-22
$9.06K
derived: sum of 2 quarters · filed 2022-11-14
$14.57K
10-Q · filed 2022-11-14
$8.24K
10-Q · filed 2021-11-22
2021-06-30$5.30K
10-Q · filed 2022-08-10
$10.80K
10-Q · filed 2022-08-10
2021-03-31$5.51K
10-Q · filed 2022-05-12
2020-12-31$26.13K
10-K/A · filed 2023-04-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
Liminatus Pharma, Inc. (LIMN)United States$0.282B
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Ocugen, Inc. (OCGN)United States$0.343B-6.34
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05